Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781629 | 1.00 | MRGPRX1 (0.55) | MRGPRX1ALDH1A1POLBCHRNB4CHRNA3 | |
| SCHEMBL14364967 | 1.00 | MRGPRX1 (0.55) | MRGPRX1ALDH1A1POLBCHRNB4CHRNA3 | |
| SCHEMBL9325051 | 0.91 | MRGPRX1 (0.48) | MRGPRX1ALDH1A1POLBCTSKGLA | |
| SCHEMBL5078507 | 0.90 | MRGPRX1 (0.49) | MRGPRX1CHRNB4CHRNA3SLC18A3TACR1 | |
| SCHEMBL700103 | 0.89 | MRGPRX1 (0.46) | MRGPRX1 | |
| Benzylamine SCHEMBL28553128 | 0.89 | MRGPRX1 (0.55) | MRGPRX1CTSKGLATACR1 | |
| SCHEMBL9322829 | 0.89 | MRGPRX1 (0.47) | MRGPRX1ALDH1A1POLB | |
| SCHEMBL9322768 | 0.86 | MRGPRX1 (0.44) | MRGPRX1SLC18A3 | |
| SCHEMBL8802582 | 0.85 | MRGPRX1 (0.43) | MRGPRX1TACR1 | |
| SCHEMBL9322784 | 0.85 | MRGPRX1 (0.43) | MRGPRX1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551833-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20050085641-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2005-04-21 | — | — | US | claimed |
| US-6861526-B2 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. (US) | 2005-03-01 | — | — | US | claimed |
| US-20040116704-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004035575-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | PFIZER PRODUCTS, INC. (US) | 2004-04-29 | — | — | WO | claimed |
| CN-112557541-B | Detection method of maropiptan citrate and related substances thereof | 河北科技大学 | 2022-07-12 | — | — | CN | disclosed |
| CN-109320510-B | Preparation method of Maropitan free base | 江苏慧聚药业有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-112557541-A | Detection method of maropiptan citrate and related substances thereof | 河北科技大学 | 2021-03-26 | — | — | CN | disclosed |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | PFIZER INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | PFIZER INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1713801-B1 | PROCESS FOR PREPARATION OF 1-(2S,3S)-2-BENZHYDR YL-N-(5-TERT-BUTYL-2-METHOXYBENZYL)QUINUCLIDIN-3-AMINE | PFIZER PROD INC (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1551833-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085641-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2005-04-21 | — | — | US | disclosed |
| US-6861526-B2 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040116704-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004035575-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | PFIZER PRODUCTS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085641-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | BCKDK, SRM, SKP1 | MRGPRX1 4032/4885ALDH1A1 941/4885POLB 3007/4885 |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | CS, GATD3, AQP1 | MRGPRX1 2986/4885ALDH1A1 690/4885POLB 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.